SMMT — Summit Therapeutics Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1599298 ·
Last close
$14.29
Market Cap
$11.09B
52W High
$29.23
52W Low
$13.81
ADV30
5,386,978
Next earnings
2026-04-30
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -195,212,000 | -189,424,000 | 647,856,000 | 106,515,000 | 101,924,000 |
| Dec 2025 | 0 | — | -224,875,000 | -219,172,000 | 751,182,000 | 225,266,000 | 92,322,000 |
| Sep 2025 | 0 | — | -234,211,000 | -231,793,000 | 261,729,000 | 238,554,000 | 69,466,000 |
| Jun 2025 | 0 | — | -568,437,000 | -565,708,000 | 324,037,000 | 297,872,000 | 64,598,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-384,053,000
Investing CF
$-334,658,000
Financing CF
$613,653,000
CapEx
$-902,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-1.60
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-2,483,583,000
Inventory
—
Receivables
—
ST Investments
$492,216,000
EBIT TTM
$-1,211,835,000
Pretax Income TTM
$-1,206,047,000
Interest Exp TTM
$0
Analysts
14
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -1,094,374,000 | -1,079,586,000 | 751,182,000 | 92,322,000 | — | -322,930,000 |
| Dec 2024 | 0 | -210,977,000 | -221,315,000 | 435,560,000 | 46,812,000 | — | -142,106,000 |
| Dec 2023 | 0 | -88,735,000 | -614,928,000 | 202,949,000 | 125,257,000 | — | -76,760,000 |
| Dec 2022 | 705,000 | -63,621,000 | -78,782,000 | 664,168,000 | 537,514,000 | — | -41,582,000 |
TTM Snapshot
Revenues TTM
$1,529,000
NetIncome TTM
$-118,506,000
OpCashFlow TTM
$0
Assets (Latest)
$435,560,000
Forward EPS
$-1.17
Max Pain — expiry 2027-01-15 (volume-derived — Yahoo OI feed degraded)
max pain strike: $15.00 · spot: $14.29 · call volume: 145 · put volume: 1,866
Expected Move to 2027-01-15:
±$9.55
(66.83%) —
implied range
$4.74 –
$23.84
· ATM straddle on $14.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RDY | DR REDDYS LABORATORIES LTD | $11.13B | $13.37 | — |
| MDGL | MADRIGAL PHARMACEUTICALS, INC. | $11.00B | $476.89 | — |
| BMRN | BIOMARIN PHARMACEUTICAL INC | $11.19B | $57.91 | — |
| ARWR | ARROWHEAD PHARMACEUTICALS, INC. | $10.33B | $73.33 | — |
| ELAN | Elanco Animal Health Inc | $12.24B | $24.50 | — |
News headlines (Yahoo Finance, 1h cache)
Summit Therapeutics Announces Proposed Public Offering of Common Stock
2026-06-09 20:47 · Yahoo
Mizuho Strategist: Healthcare Is Now a Value Sector as Pharma Stocks Underperform Tech
2026-06-07 13:30 · Yahoo
Summit Therapeutics COO, CFO & Director Acquires 1.6% More Stock
2026-06-07 12:59 · Yahoo
Summit Therapeutics (SMMT) Reveals Phase II AK112-206 Trial Data
2026-06-05 16:36 · Yahoo
Summit Therapeutics to Participate in the 47th Annual Goldman Sachs Global Healthcare Conference
2026-06-04 20:30 · Yahoo
All You Need to Know About Summit Therapeutics (SMMT) Rating Upgrade to Buy
2026-06-04 16:00 · Yahoo
Summit (SMMT) Reports Positive Phase III Overall Survival Data for Ivonescimab in Advanced NSCLC
2026-06-04 09:05 · Yahoo
Pharma is betting big on PD-1/VEGF bispecifics. But are companies chasing the wrong target?
2026-06-04 08:55 · Yahoo
Assessing Summit Therapeutics (SMMT) Valuation After A Mixed Share Price And Long Term Return Profile
2026-06-04 02:13 · Yahoo
ASCO26: Bispecific antibody and RET fusion-targeting assets garner attention in NSCLC
2026-06-03 00:44 · Yahoo
Recent Insider Activity
| Filed | Trade | Insider | Title | Type | Price | Qty | Value |
|---|---|---|---|---|---|---|---|
| 2026-06-04 17:45:03 | 2026-06-04 | Zanganeh Mahkam | Co-CEO, 10% | P - Purchase | 14.6 | 100000 | 1460000 |
| 2026-06-04 18:08:26 | 2026-06-04 | Duggan Robert W | Co-CEO, 10% | P - Purchase | 14.6 | 100000 | 1460000 |
| 2026-06-04 16:40:51 | 2026-06-04 | Soni Manmeet Singh | COO, CFO | P - Purchase | 14.45 | 50000 | 722250 |